Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial
A trial studying a higher dose of Biogen’s spinal muscular atrophy (SMA) drug Spinraza (nusinersen) has met the primary endpoint …
A trial studying a higher dose of Biogen’s spinal muscular atrophy (SMA) drug Spinraza (nusinersen) has met the primary endpoint …
The US Food and Drug Administration (FDA) has converted the accelerated approval for Travere Therapeutics’ Filspari (sparsentan) to full approval …
The atopic dermatitis (AD) market is facing increased growth, with a projected market value of $16.7bn by 2030 for the …
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) has warned men taking epilepsy medication valproate and their partners to use …
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive …
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147, a treatment aimed …
NImmune Biopharma has entered a research partnership with BioTherapeutics, aimed at propelling the development of new precision medicines in the …
German life science company Evotec has announced a collaboration with X-Chem to accelerate early-stage drug discovery-leveraging technology. The partnership aims to …
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals and Shilpa Medicare’s oncology product BORUZU for subcutaneous administration. BORUZU, …
On the last day of the European Society of Cardiology (ESC) 2024 Congress (2 September), a panel discussed the therapeutic …
The results of two subanalyses of the PACMAN-AMI trial were presented on the final day (2 September) of the European …
As the number of mpox-related deaths in the Democratic Republic of Congo (DRC) and neighbouring countries continues to climb, international …
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug …
Moderna has announced its mRNA vaccine in development for mpox is more effective than Bavarian Nordics Jynneos in prevention of …
Investors are rallying around the promise of cross-species transplantation, enabling eGenesis to close a $191m Series D financing round to …